CL2011002863A1 - Uso de una composicion que comprende nandrolona y un compuesto de vitamina d para preparar un medicamento parenteral util para el tratamiento o prevencion de la fragilidad en un paciente de edad avanzada; y composicion que comprende nandrolona y un compuesto de vitamina d, en un portador liquido adecuado para administracion parenteral. - Google Patents
Uso de una composicion que comprende nandrolona y un compuesto de vitamina d para preparar un medicamento parenteral util para el tratamiento o prevencion de la fragilidad en un paciente de edad avanzada; y composicion que comprende nandrolona y un compuesto de vitamina d, en un portador liquido adecuado para administracion parenteral.Info
- Publication number
- CL2011002863A1 CL2011002863A1 CL2011002863A CL2011002863A CL2011002863A1 CL 2011002863 A1 CL2011002863 A1 CL 2011002863A1 CL 2011002863 A CL2011002863 A CL 2011002863A CL 2011002863 A CL2011002863 A CL 2011002863A CL 2011002863 A1 CL2011002863 A1 CL 2011002863A1
- Authority
- CL
- Chile
- Prior art keywords
- vitamin
- compound
- nandrolone
- composition
- parenteral
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A61K31/592—9,10-Secoergostane derivatives, e.g. ergocalciferol, i.e. vitamin D2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/06—Anabolic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Nutrition Science (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Método de tratamiento de la fragilidad de un paciente de edad avanzada que comprende la administración parenteral de las dosis efectivas de una combinación de esteroide anabólico y de un compuesto de vitamina D; composición farmacéutica que comprende un esteroide anabólico y un compuesto de vitamina D; un dispositivo de inyección.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP09168522A EP2289555A1 (en) | 2009-08-24 | 2009-08-24 | Method of treating frailty |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2011002863A1 true CL2011002863A1 (es) | 2012-04-13 |
Family
ID=42016317
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2011002863A CL2011002863A1 (es) | 2009-08-24 | 2011-11-14 | Uso de una composicion que comprende nandrolona y un compuesto de vitamina d para preparar un medicamento parenteral util para el tratamiento o prevencion de la fragilidad en un paciente de edad avanzada; y composicion que comprende nandrolona y un compuesto de vitamina d, en un portador liquido adecuado para administracion parenteral. |
Country Status (23)
Country | Link |
---|---|
US (1) | US10543217B2 (es) |
EP (2) | EP2289555A1 (es) |
JP (2) | JP2013502457A (es) |
KR (1) | KR20120053987A (es) |
CN (1) | CN102421450B (es) |
AU (1) | AU2010287043B2 (es) |
BR (1) | BRPI1011567B1 (es) |
CA (1) | CA2759815C (es) |
CL (1) | CL2011002863A1 (es) |
CO (1) | CO6460777A2 (es) |
DK (1) | DK2470214T3 (es) |
ES (1) | ES2425095T3 (es) |
IL (1) | IL216456A (es) |
MX (1) | MX2011011905A (es) |
MY (1) | MY162621A (es) |
NZ (1) | NZ596057A (es) |
PL (1) | PL2470214T3 (es) |
PT (1) | PT2470214E (es) |
RU (1) | RU2635541C2 (es) |
SG (1) | SG176135A1 (es) |
UA (1) | UA107928C2 (es) |
WO (1) | WO2011025368A1 (es) |
ZA (1) | ZA201108056B (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101970893B1 (ko) | 2017-10-18 | 2019-04-19 | 동아대학교 산학협력단 | 노쇠 여부 스크리닝 장치 |
CN109364034B (zh) * | 2018-11-26 | 2021-05-04 | 正大制药(青岛)有限公司 | 一种骨化三醇制剂及其制备方法 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4308264A (en) * | 1981-01-28 | 1981-12-29 | Abbott Laboratories | Stabilized, dilute aqueous preparation of 1α,25-dihydroxycholecalciferol for neonatal administration |
BR9205983A (pt) * | 1991-05-06 | 1994-08-02 | Procter & Gamble | Suplementos de cálcio e vitamina d combinados |
US5898038A (en) * | 1996-03-19 | 1999-04-27 | Board Of Regents, The University Of Texas System | Treatment of osteoporosis and metabolic bone disorders with nitric oxide substrate and/or donors |
US6031000A (en) * | 1998-06-23 | 2000-02-29 | Iowa State University Research Foundation, Inc. | Composition comprising β-hydroxy-β-methylbutyric acid and at least one amino acid and methods of use |
US7261905B2 (en) * | 1999-04-07 | 2007-08-28 | Pure Bioscience | Disinfectant and method of making |
US6638239B1 (en) * | 2000-04-14 | 2003-10-28 | Glaukos Corporation | Apparatus and method for treating glaucoma |
GB0307728D0 (en) | 2003-04-03 | 2003-05-07 | Tesla Engineering Ltd | Coil structure for magnetic resonance imaging |
US8795693B2 (en) * | 2003-08-04 | 2014-08-05 | Foamix Ltd. | Compositions with modulating agents |
FR2860236B1 (fr) * | 2003-09-25 | 2006-01-06 | Theraptosis | Peptides possedant notamment une activite anti-angiogenique et leurs applications en therapeutique |
EP1896134A2 (en) * | 2005-06-13 | 2008-03-12 | Rigel Pharmaceuticals, Inc. | Methods and compositions for treating degenerative bone disorders |
CA2882048C (en) * | 2006-02-03 | 2020-03-24 | Proventiv Therapeutics, Llc | Treating vitamin d insufficiency and deficiency with 25-hydroxyvitamin d2 and 25-hydroxyvitamin d3 |
CA2558202A1 (en) * | 2006-09-14 | 2006-11-23 | Reinhold W. Vieth | Vitamin d compositions and method of administration to infants |
RU2363488C1 (ru) * | 2007-11-26 | 2009-08-10 | Закрытое акционерное общество "Эксесс Байосаинс" | Фармацевтическая композиция на основе пептида, регулирующего нарушения ангиогенеза, и способ ее применения |
US9259430B2 (en) * | 2008-12-09 | 2016-02-16 | Metabolic Technologies, Inc. | Nutritional intervention for improving muscular function and strength |
RU2410392C2 (ru) * | 2009-02-16 | 2011-01-27 | Учреждение Российской академии медицинских наук Научно-исследовательский институт фармакологии имени В.В. Закусова РАМН | Дипептидные миметики нейротрофинов ngf и bdnf |
-
2009
- 2009-08-24 EP EP09168522A patent/EP2289555A1/en not_active Ceased
-
2010
- 2010-08-23 DK DK10747526.1T patent/DK2470214T3/da active
- 2010-08-23 KR KR1020117026830A patent/KR20120053987A/ko not_active Application Discontinuation
- 2010-08-23 SG SG2011084944A patent/SG176135A1/en unknown
- 2010-08-23 JP JP2012526677A patent/JP2013502457A/ja active Pending
- 2010-08-23 EP EP10747526.1A patent/EP2470214B1/en active Active
- 2010-08-23 AU AU2010287043A patent/AU2010287043B2/en not_active Ceased
- 2010-08-23 WO PCT/NL2010/050524 patent/WO2011025368A1/en active Application Filing
- 2010-08-23 US US13/318,650 patent/US10543217B2/en not_active Expired - Fee Related
- 2010-08-23 PT PT107475261T patent/PT2470214E/pt unknown
- 2010-08-23 RU RU2011146830A patent/RU2635541C2/ru active
- 2010-08-23 CA CA2759815A patent/CA2759815C/en not_active Expired - Fee Related
- 2010-08-23 MY MYPI2011005129A patent/MY162621A/en unknown
- 2010-08-23 CN CN201080020393.2A patent/CN102421450B/zh not_active Expired - Fee Related
- 2010-08-23 BR BRPI1011567-6A patent/BRPI1011567B1/pt not_active IP Right Cessation
- 2010-08-23 UA UAA201113554A patent/UA107928C2/ru unknown
- 2010-08-23 MX MX2011011905A patent/MX2011011905A/es active IP Right Grant
- 2010-08-23 NZ NZ596057A patent/NZ596057A/xx not_active IP Right Cessation
- 2010-08-23 PL PL10747526T patent/PL2470214T3/pl unknown
- 2010-08-23 ES ES10747526T patent/ES2425095T3/es active Active
-
2011
- 2011-11-02 ZA ZA2011/08056A patent/ZA201108056B/en unknown
- 2011-11-14 CL CL2011002863A patent/CL2011002863A1/es unknown
- 2011-11-17 IL IL216456A patent/IL216456A/en active IP Right Grant
- 2011-11-17 CO CO11156685A patent/CO6460777A2/es not_active Application Discontinuation
-
2015
- 2015-10-15 JP JP2015203528A patent/JP6279529B2/ja not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
SG176135A1 (en) | 2011-12-29 |
CN102421450A (zh) | 2012-04-18 |
IL216456A (en) | 2017-04-30 |
ES2425095T3 (es) | 2013-10-11 |
MY162621A (en) | 2017-06-30 |
PT2470214E (pt) | 2013-08-27 |
CN102421450B (zh) | 2015-09-09 |
AU2010287043B2 (en) | 2014-11-06 |
DK2470214T3 (da) | 2013-08-12 |
BRPI1011567A2 (pt) | 2016-04-05 |
WO2011025368A1 (en) | 2011-03-03 |
ZA201108056B (en) | 2012-07-25 |
AU2010287043A1 (en) | 2011-11-10 |
RU2635541C2 (ru) | 2017-11-13 |
BRPI1011567B1 (pt) | 2019-05-14 |
CO6460777A2 (es) | 2012-06-15 |
JP6279529B2 (ja) | 2018-02-14 |
MX2011011905A (es) | 2012-01-30 |
JP2016011313A (ja) | 2016-01-21 |
UA107928C2 (en) | 2015-03-10 |
EP2470214B1 (en) | 2013-05-15 |
IL216456A0 (en) | 2012-01-31 |
CA2759815C (en) | 2018-06-12 |
CA2759815A1 (en) | 2011-03-03 |
RU2011146830A (ru) | 2013-10-10 |
NZ596057A (en) | 2013-07-26 |
EP2470214A1 (en) | 2012-07-04 |
EP2289555A1 (en) | 2011-03-02 |
PL2470214T3 (pl) | 2013-12-31 |
KR20120053987A (ko) | 2012-05-29 |
US10543217B2 (en) | 2020-01-28 |
US20120196837A1 (en) | 2012-08-02 |
JP2013502457A (ja) | 2013-01-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112016000194A8 (pt) | forma de dosagem resistente à violação contendo o polímero de acetato de etileno-vinila | |
CL2012002356A1 (es) | Compuestos heterociclicos acidos derivados de ariltriazolonas ligadas a bisarilo, inhibidores de receptores de vasopresina v1a y v2; procedimiento de preparacion; composicion farmaceutica; y su uso para tratar y/o prevenir insuficiencia cardiaca aguda y cronica, hiponatremia, entre otras. | |
SV2015005115A (es) | Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades | |
AR095338A1 (es) | Método de tratamiento no tóxico para la abstinencia de drogas | |
CL2015002733A1 (es) | Composición farmacéutica de clorhidrato de s-cetamina. | |
CO6361944A2 (es) | Combinacion de una insulina y un agonista de glp-1 | |
AR090491A1 (es) | Tratamiento de la esclerosis multiple con una combinacion de laquinimod y fumarato de dimetilo | |
AR097619A1 (es) | Uso de inhibidores de acetil-coa carboxilasa para tratar acné vulgaris | |
CL2011002858A1 (es) | Uso de una composicion farmaceutica transmucosa oral que comprende dexmedetomidina y una sal farmaceuticamente aceptable y un excipiente farmaceuticamente aceptable para preparar un medicamento util para tratar o prevenir el dolor. | |
CL2014002935A1 (es) | Metodo para tratar un paciente humano con esclerosis multiple con laquinimod, en una dosis diaria de alrededor de 1,2mg; un aforma de dosificacion unitaria oral de 1,2 mg de laquinimod y un portador | |
CR20140005A (es) | Una nueva composición terapéutica que contiene apomorfina como principio activo | |
GT201400059A (es) | Derivados de estra-1,3,5(10),16-tetraen-3-carboxamida, proceidmientos para su preparación, preparados farmacéuticos que los contienen, así como su uso para la preparacion de medicamentos | |
AR096892A1 (es) | Una combinación farmacéutica para el tratamiento del melanoma | |
MX2016008138A (es) | Sistema para el suministro transdermico de ingredientes activos. | |
PE20140255A1 (es) | Tableta dispersable en forma oral | |
EA201400737A1 (ru) | Система доставки на основе множества пеллет с немедленным высвобождением активного вещества | |
CL2010000524A1 (es) | Uso de una composición tópica que comprende 3,75% de imiquimod y un portador farmacéuticamente aceptable para preparar un medicamento útil para tratar verrugas genitales o perianales. | |
AR088204A1 (es) | Medicamentos para el tratamiento de la rinitis alergica que comprenden un antagonista de pgd2 y un antagonista de histamina | |
CO6311083A2 (es) | 4-((1r,3s)-6-cloro-3-fenilindan-1-il)-1,2,2-trimetilpiperazina para el tratamiento de la disfunción cognitiva | |
MX370898B (es) | Agente terapéutico y/o preventivo que comprende un derivado de 1-indansulfamida para el dolor. | |
AR098832A1 (es) | Uso de laquinimod para retrasar la progresión de la enfermedad de huntington | |
AR065139A1 (es) | Medicamento para el tratamiento de la endometriosis | |
BR112012014107B8 (pt) | sistema terapêutico transdérmico (tts) e processo de produção de tts | |
CL2011002863A1 (es) | Uso de una composicion que comprende nandrolona y un compuesto de vitamina d para preparar un medicamento parenteral util para el tratamiento o prevencion de la fragilidad en un paciente de edad avanzada; y composicion que comprende nandrolona y un compuesto de vitamina d, en un portador liquido adecuado para administracion parenteral. | |
CL2010001594A1 (es) | Uso de nifurtimox para preparar un medicamento útil en el tratamiento de enfermedades causadas por trichomonadida. |